Current understanding on the role of standard and immunoproteasomes in inflammatory/immunological pathways of multiple sclerosis

Autoimmune Diseases

Volumn 2014, Issue , 2014, Pages

  Bellavista, Elena ^a   Santoro, Aurelia ^a   Galimberti, Daniela ^b   Comi, Cristoforo ^c   Luciani, Fabio ^d   Mishto, Michele ^a,e  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME; PROTEASOME INHIBITOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INTESTINE FLORA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEINASE INHIBITION; REVIEW; TH17 CELL;

EID: 84893204344     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2014/739705     Document Type: Review

References (127)

1. Frohman E. M., Racke M. K., Raine C. S., Multiple sclerosis. The plaque and its pathogenesis. The New England Journal of Medicine 2006 354 9 942 955 2-s2.0-33644607018 10.1056/NEJMra052130
2. Stys P. K., Zamponi G. W., van Minnen J., Geurts J. J., Will the real multiple sclerosis please stand up? Nature Reviews Neuroscience 2012 13 7 507 514
3. Compston A., Coles A., Multiple sclerosis. The Lancet 2008 372 9648 1502 1517 2-s2.0-54149084585 10.1016/S0140-6736(08)61620-7
4. Giovannoni G., Ebers G., Multiple sclerosis: the environment and causation. Current Opinion in Neurology 2007 20 3 261 268 2-s2.0-34248364052 10.1097/WCO.0b013e32815610c2 (Pubitemid 46743106)
5. Jilek S., Schluep M., Harari A., Canales M., Lysandropoulos A., Zekeridou A., Pantaleo G., Du Pasquier R. A., HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis. Journal of Immunology 2012 188 9 4671 4680 2-s2.0-84860330754 10.4049/jimmunol.1103100
6. Fugger L., Friese M. A., Bell J. I., From genes to function: the next challenge to understanding multiple sclerosis. Nature Reviews Immunology 2009 9 6 408 417 2-s2.0-67349179231 10.1038/nri2554
7. Trapp B. D., Nave K.-A., Multiple sclerosis: an immune or neurodegenerative disorder? Annual Review of Neuroscience 2008 31 247 269 2-s2.0-48249139449 10.1146/annurev.neuro.30.051606.094313
8. Goldberg A. L., Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochemical Society Transactions 2007 35 1 12 17 2-s2.0-33847066706 10.1042/BST0350012
9. Dahlmann B., Role of proteasomes in disease. BMC Biochemistry 2007 8 1, article S3 2-s2.0-38449099679 10.1186/1471-2091-8-S1-S3 (Pubitemid 351814004)
10. Schmidt F., Dahlmann B., Hustoft H. K., Koehler C. J., Strozynski M., Klo A., Zimny-Arndt U., Jungblut P. R., Thiede B., Quantitative proteome analysis of the 20S proteasome of apoptotic Jurkat T cells. Amino Acids 2011 41 2 351 361 2-s2.0-79960244404 10.1007/s00726-010-0575-6
11. Ebstein F., Kloetzel P.-M., Krüger E., Seifert U., Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cellular and Molecular Life Sciences 2012 69 15 2543 2558 2-s2.0-84857479456 10.1007/s00018-012-0938-0
12. Weissman A. M., Shabek N., Ciechanover A., The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. Nature Reviews Molecular Cell Biology 2011 12 9 605 620 2-s2.0-80051978811 10.1038/nrm3173
13. Bochtler M., Ditzel L., Groll M., Hartmann C., Huber R., The proteasome. Annual Review of Biophysics and Biomolecular Structure 1999 28 295 317 2-s2.0-0033033183 10.1146/annurev.biophys.28.1.295 (Pubitemid 29319261)
14. Voges D., Zwickl P., Baumeister W., The 26S proteasome: a molecular machine designed for controlled proteolysis. Annual Review of Biochemistry 1999 68 1015 1068 2-s2.0-0032867676 10.1146/annurev.biochem.68.1.1015 (Pubitemid 29449214)
15. Pintado C., Gavilán M. P., Gavilán E., García-Cuervo L., Gutiérrez A., Vitorica J., Castaño A., Ríos R. M., Ruano D., Lipopolysaccharide-induced neuroinflammation leads to the accumulation of ubiquitinated proteins and increases susceptibility to neurodegeneration induced by proteasome inhibition in rat hippocampus. Journal of Neuroinflammation 2012 9 1, article 87 2-s2.0-84860499027 10.1186/1742-2094-9-87
16. Ferrington D. A., Gregerson D. S., Immunoproteasomes: structure, function, and antigen presentation. Progress in Molecular Biology and Translational Science 2012 109 75 112
17. Qureshi N., Morrison D. C., Reis J., Proteasome protease mediated regulation of cytokine induction and inflammation. Biochimica et Biophysica Acta 2012 1823 11 2087 2093
18. Zheng J., Bizzozero O. A., Decreased activity of the 20S proteasome in the brain white matter and gray matter of patients with multiple schlerosis. Journal of Neurochemistry 2011 117 1 143 153 2-s2.0-79952551776 10.1111/j.1471-4159.2011.07182.x
19. Orre M., Kamphuis W., Dooves S., Kooijman L., Chan E. T., Kirk C. J., Dimayuga Smith V., Koot S., Mamber C., Jansen A. H., Ovaa H., Hol E. M., Reactive glia show increased immunoproteasome activity in Alzheimer's disease. Brain 2013 136 5 1415 1431
20. Gohlke S., Mishto M., Textoris-Taube K., Keller C., Giannini C., Vasuri F., Capizzi E., 'Errico-Grigioni A D., Kloetzel P. M., Dahlmann B., Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities. Age 2013 10.007/s11357-013-9543-x
21. Giannini C., Kloss A., Gohlke S., Mishto M., Nicholson T. P., Sheppard P. W., Kloetzel P. M., Dahlmann B., Poly-ub-substrate-degradative activity of 26S proteasome is not impaired in the aging rat brain. PLoS ONE 2013 8 5 e64042
22. Mishto M., Bellavista E., Ligorio C., Textoris-Taube K., Santoro A., Giordano M., D'Alfonso S., Listì F., Nacmias B., Cellini E., Leone M., Grimaldi L. M. E., Fenoglio C., Esposito F., Martinelli-Boneschi F., Galimberti D., Scarpini E., Seifert U., Amato M. P., Caruso C., Foschini M. P., Kloetzel P. M., Franceschi C., Immunoproteasome LMP2 60HH variant alters MBP epitope generation and reduces the risk to develop multiple sclerosis in Italian female population. PLoS ONE 2010 5 2 2-s2.0-77949524663 10.1371/journal.pone.0009287 e9287
23. Zheng J., Dasgupta A., Bizzozero O. A., Changes in 20S subunit composition are largely responsible for altered proteasomal activities in experimental autoimmune encephalomyelitis. Journal of Neurochemistry 2012 121 3 486 494 2-s2.0-84859610057 10.1111/j.1471-4159.2012.07699.x
24. Mishto M., Ligorio C., Bellavista E., Martucci M., Santoro A., Giulioni M., Marucci G., Franceschi C., Immunoproteasome expression is induced in mesial temporal lobe epilepsy. Biochemical and Biophysical Research Communications 2011 408 1 65 70 2-s2.0-79955424238 10.1016/j.bbrc.2011.03.117
25. Kremer M., Henn A., Kolb C., Basler M., Moebius J., Guillaume B., Leist M., Van Den Eynde B. J., Groettrup M., Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. Journal of Immunology 2010 185 9 5549 5560 2-s2.0-78149477289 10.4049/jimmunol.1001517
26. Gavilán M. P., Castaño A., Torres M., Portavella M., Caballero C., Jiménez S., García-Martínez A., Parrado J., Vitorica J., Ruano D., Age-related increase in the immunoproteasome content in rat hippocampus: molecular and functional aspects. Journal of Neurochemistry 2009 108 1 260 272 2-s2.0-57249111795 10.1111/j.1471-4159.2008.05762.x
27. Mishto M., Bellavista E., Santoro A., Stolzing A., Ligorio C., Nacmias B., Spazzafumo L., Chiappelli M., Licastro F., Sorbi S., Pession A., Ohm T., Grune T., Franceschi C., Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains. Neurobiology of Aging 2006 27 1 54 66 2-s2.0-27744461250 10.1016/j.neurobiolaging.2004.12.004 (Pubitemid 41627950)
28. Bellavista E., Mishto M., Santoro A., Bertoni-Freddari C., Sessions R. B., Franceschi C., Immunoproteasome in Macaca fascicularis: no age-dependent modification of abundance and activity in the brain and insight into an in silico structural model. Rejuvenation Research 2008 11 1 73 82 2-s2.0-39449101794 10.1089/rej.2007.0559 (Pubitemid 351271622)
29. Groettrup M., Kirk C. J., Basler M., Proteasomes in immune cells: more than peptide producers? Nature Reviews Immunology 2010 10 1 73 78 2-s2.0-72949103056 10.1038/nri2687
30. Hussong S. A., Kapphahn R. J., Phillips S. L., Maldonado M., Ferrington D. A., Immunoproteasome deficiency alters retinal proteasome's response to stress. Journal of Neurochemistry 2010 113 6 1481 1490 2-s2.0-77953101405 10.1111/j.1471-4159.2010.06688.x
31. Seifert U., Bialy L. P., Ebstein F., Bech-Otschir D., Voigt A., Schröter F., Prozorovski T., Lange N., Steffen J., Rieger M., Kuckelkorn U., Aktas O., Kloetzel P.-M., Krüger E., Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010 142 4 613 624 2-s2.0-77955596988 10.1016/j.cell.2010.07.036
32. Nathan J. A., Spinnenhirn V., Schmidtke G., Basler M., Groettrup M., Goldberg A. L., Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152 5 1184 1194
33. Friese M. A., Fugger L., Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 2005 128 8 1747 1763 2-s2.0-23444434940 10.1093/brain/awh578 (Pubitemid 41373647)
34. Yokote H., Miyake S., Croxford J. L., Oki S., Mizusawa H., Yamamura T., NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. The American Journal of Pathology 2008 173 6 1714 1723 2-s2.0-57149094667 10.2353/ajpath.2008.080622
35. Tsuchida T., Parker K. C., Turner R. V., McFarland H. F., Coligan J. E., Biddison W. E., Autoreactive CD8+ T-cell responses to human myelin protein-derived peptides. Proceedings of the National Academy of Sciences of the United States of America 1994 91 23 10859 10863 2-s2.0-0028143869 10.1073/pnas.91.23.10859 (Pubitemid 24349584)
36. Jurewicz A., Biddison W. E., Antel J. P., MHC class I-restricted lysis of human oligodendrocytes by myelin basic protein peptide-specific CD8 T lymphocytes. Journal of Immunology 1998 160 6 3056 3059 2-s2.0-0032521030 (Pubitemid 28136763)
37. Zang Y. C. Q., Li S., Rivera V. M., Hong J., Robinson R. R., Breitbach W. T., Killian J., Zhang J. Z., Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. Journal of Immunology 2004 172 8 5120 5127 2-s2.0-1842423766 (Pubitemid 38456441)
38. Zaiss D. M. W., Bekker C. P. J., Gröne A., Lie B. A., Sijts A. J. A. M., Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. Journal of Immunology 2011 187 5 2302 2309 2-s2.0-80052679971 10.4049/jimmunol.1101003
39. Lünemann J. D., Edwards N., Muraro P. A., Hayashi S., Cohen J. I., Münz C., Martin R., Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 2006 129 6 1493 1506 2-s2.0-33745104765 10.1093/brain/awl067 (Pubitemid 43999382)
40. Jilek S., Schluep M., Meylan P., Vingerhoets F., Guignard L., Monney A., Kleeberg J., Le Goff G., Pantaleo G., Du Pasquier R. A., Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 2008 131 7 1712 1721 2-s2.0-46849084346 10.1093/brain/awn108 (Pubitemid 351957461)
41. Höllsberg P., Hansen H. J., Haahr S., Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clinical and Experimental Immunology 2003 132 1 137 143 2-s2.0-0347997289 10.1046/j.1365-2249.2003.02114.x (Pubitemid 36418916)
42. Cepok S., Zhou D., Srivastava R., Nessler S., Stei S., Büssow K., Sommer N., Hemmer B., Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. Journal of Clinical Investigation 2005 115 5 1352 1360 2-s2.0-18244378502 10.1172/JCI200523661 (Pubitemid 40629055)
43. Ishizuka J., Grebe K., Shenderov E., Peters B., Chen Q., Peng Y., Wang L., Dong T., Pasquetto V., Oseroff C., Sidney J., Hickman H., Cerundolo V., Sette A., Bennink J. R., McMichael A., Yewdell J. W., Quantitating T cell cross-reactivity for unrelated peptide antigens. Journal of Immunology 2009 183 7 4337 4345 2-s2.0-70449732759 10.4049/jimmunol.0901607
44. Vigneron N., Stroobant V., Chapiro J., Ooms A., Degiovanni G., Morel S., Van Der Bruggen P., Boon T., Van Den Eynde B. J., An antigenic peptide produced by peptide splicing in the proteasome. Science 2004 304 5670 587 590 2-s2.0-2142644458 10.1126/science.1095522 (Pubitemid 38541917)
45. Dalet A., Vigneron N., Stroobant V., Hanada K.-I., Van Den Eynde B. J., Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5. Journal of Immunology 2010 184 6 3016 3024 2-s2.0-77951926376 10.4049/jimmunol.0901277
46. Liepe J., Mishto M., Textoris-Taube K., Janek K., Keller C., Henklein P., Kloetzel P. M., Zaikin A., The 20S proteasome splicing activity discovered by SpliceMet. PLoS Computational Biology 2010 6 6 e1000830 2-s2.0-77956197363 10.1371/journal.pcbi.1000830
47. Mishto M., Goede A., Taube K. T., Keller C., Janek K., Henklein P., Niewienda A., Kloss A., Gohlke S., Dahlmann B., Enenkel C., Michael Kloetzel P., Driving forces of proteasome-catalyzed peptide splicing in yeast and humans. Molecular and Cellular Proteomics 2012 11 10 1008 1023
48. Rammensee H.-G., Protein surgery. Nature 2004 427 6971 203 204 2-s2.0-1642512398 10.1038/427203a (Pubitemid 38112021)
49. Mori K., Itoi M., Tsukamoto N., Kubo H., Amagai T., The perivascular space as a path of hematopoietic progenitor cells and mature T cells between the blood circulation and the thymic parenchyma. International Immunology 2007 19 6 745 753 2-s2.0-34447570906 10.1093/intimm/dxm041 (Pubitemid 47073264)
50. Bettelli E., Carrier Y., Gao W., Korn T., Strom T. B., Oukka M., Weiner H. L., Kuchroo V. K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 441 7090 235 238 2-s2.0-33646577466 10.1038/nature04753
51. Maddur M. S., Miossec P., Kaveri S. V., Bayry J., Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. The American Journal of Pathology 2012 181 1 8 18
52. Tzartos J. S., Friese M. A., Craner M. J., Palace J., Newcombe J., Esiri M. M., Fugger L., Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. The American Journal of Pathology 2008 172 1 146 155 2-s2.0-38749143286 10.2353/ajpath.2008.070690 (Pubitemid 351186376)
53. Carlson T., Kroenke M., Rao P., Lane T. E., Segal B., The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. Journal of Experimental Medicine 2008 205 4 811 823 2-s2.0-42249114634 10.1084/jem.20072404 (Pubitemid 351549880)
54. Siffrin V., Radbruch H., Glumm R., Niesner R., Paterka M., Herz J., Leuenberger T., Lehmann S. M., Luenstedt S., Rinnenthal J. L., Laube G., Luche H., Lehnardt S., Fehling H.-J., Griesbeck O., Zipp F., In Vivo imaging of partially reversible Th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 2010 33 3 424 436 2-s2.0-77957056123 10.1016/j.immuni.2010.08.018
55. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., Sudo K., Iwakura Y., IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. Journal of Immunology 2006 177 1 566 573 2-s2.0-33745321276 (Pubitemid 43939170)
56. Cosmi L., Maggi L., Santarlasci V., Capone M., Cardilicchia E., Frosali F., Querci V., Angeli R., Matucci A., Fambrini M., Liotta F., Parronchi P., Maggi E., Romagnani S., Annunziato F., Identification of a novel subset of human circulating memory CD4+ T cells that produce both IL-17A and IL-4. Journal of Allergy and Clinical Immunology 2010 125 1-3 222-30.e1 222-30.e4 2-s2.0-73149118287 10.1016/j.jaci.2009.10.012
57. Berer K., Krishnamoorthy G., Commensal gut flora and brain autoimmunity: a love or hate affair? Acta Neuropathologica 2012 123 5 639 651 2-s2.0-84856604833 10.1007/s00401-012-0949-9
58. Bienenstock J., Collins S., 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: psycho-neuroimmunology and the intestinal microbiota: clinical observations and basic mechanisms. Clinical and Experimental Immunology 2010 160 1 85 91 2-s2.0-77949362543 10.1111/j.1365-2249. 2010.04124.x
59. Collins S. M., Surette M., Bercik P., The interplay between the intestinal microbiota and the brain. Nature Reviews Microbiology 2012 10 11 735 742
60. Ivanov I. I., Atarashi K., Manel N., Brodie E. L., Shima T., Karaoz U., Wei D., Goldfarb K. C., Santee C. A., Lynch S. V., Tanoue T., Imaoka A., Itoh K., Takeda K., Umesaki Y., Honda K., Littman D. R., Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009 139 3 485 498 2-s2.0-70350343544 10.1016/j.cell.2009.09.033
61. O'Mahony C., Scully P., O'Mahony D., Murphy S., O'Brien F., Lyons A., Sherlock G., MacSharry J., Kiely B., Shanahan F., O'Mahony L., Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF- B activation. PLoS Pathogens 2008 4 8 2-s2.0-50849119097 10.1371/journal.ppat. 1000112 e1000112
62. Atarashi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y., Cheng G., Yamasaki S., Saito T., Ohba Y., Taniguchi T., Takeda K., Hori S., Ivanov I. I., Umesaki Y., Itoh K., Honda K., Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011 331 6015 337 341 2-s2.0-78650667577 10.1126/science.1198469
63. Jamshidian A., Shaygannejad V., Pourazar A., Zarkesh-Esfahani S. H., Gharagozloo M., Biased Treg/Th17 balance away from regulatory toward inflammatory phenotype in relapsed multiple sclerosis and its correlation with severity of symptoms. Journal of Neuroimmunology 2013 262 1-2 106 112
64. Lavasani S., Dzhambazov B., Nouri M., Fåk F., Buske S., Molin G., Thorlacius H., Alenfall J., Jeppsson B., Weström B., A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS ONE 2010 5 2 2-s2.0-77749322389 10.1371/journal.pone.0009009 e9009
65. Ochoa-Repáraz J., Mielcarz D. W., Ditrio L. E., Burroughs A. R., Foureau D. M., Haque-Begum S., Kasper L. H., Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. Journal of Immunology 2009 183 10 6041 6050 2-s2.0-77249096486 10.4049/jimmunol.0900747
66. Ochoa-Repáraz J., Mielcarz D. W., Wang Y., Begum-Haque S., Dasgupta S., Kasper D. L., Kasper L. H., A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunology 2010 3 5 487 495 2-s2.0-77955913743 10.1038/mi.2010.29
67. Lee Y. K., Menezes J. S., Umesaki Y., Mazmanian S. K., Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2011 108 supplement 1 4615 4622 2-s2.0-79952748674 10.1073/pnas.1000082107
68. Berer K., Mues M., Koutrolos M., AlRasbi Z., Boziki M., Johner C., Wekerle H., Krishnamoorthy G., Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011 479 7374 538 541 2-s2.0-81855167104 10.1038/nature10554
69. Muchamuel T., Basler M., Aujay M. A., Suzuki E., Kalim K. W., Lauer C., Sylvain C., Ring E. R., Shields J., Jiang J., Shwonek P., Parlati F., Demo S. D., Bennett M. K., Kirk C. J., Groettrup M., A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nature Medicine 2009 15 7 781 787 2-s2.0-67650388103 10.1038/nm.1978
70. Kalim K. W., Basler M., Kirk C. J., Groettrup M., Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. Journal of Immunology 2012 189 8 4182 4193
71. Strober W., Fuss I., Mannon P., The fundamental basis of inflammatory bowel disease. Journal of Clinical Investigation 2007 117 3 514 521 2-s2.0-33847381116 10.1172/JCI30587 (Pubitemid 46348505)
72. Schmidt N., Gonzalez E., Visekruna A., Kühl A. A., Loddenkemper C., Mollenkopf H., Kaufmann S. H. E., Steinhoff U., Joeris T., Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 2010 59 7 896 906 2-s2.0-77954008149 10.1136/gut.2009.203554
73. Basler M., Dajee M., Moll C., Groettrup M., Kirk C. J., Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. Journal of Immunology 2010 185 1 634 641 2-s2.0-77956198116 10.4049/jimmunol.0903182
74. Oh S., Cudrici C., Ito T., Rus H., B-cells and humoral immunity in multiple sclerosis. Implications for therapy. Immunologic Research 2008 40 3 224 234 2-s2.0-46149083938 10.1007/s12026-007-8009-6 (Pubitemid 351903819)
75. Engel P., Gómez-Puerta J. A., Ramos-Casals M., Lozano F., Bosch X., Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacological Reviews 2011 63 1 127 156 2-s2.0-79952024055 10.1124/pr.109.002006
76. Chan A. C., B cell immunotherapy in autoimmunity: 2010 update. Molecular Immunology 2011 48 11 1344 1347 2-s2.0-79956330472 10.1016/j.molimm.2010.11.021
77. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Aloisi F., Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathology 2004 14 2 164 174 2-s2.0-2442708947 (Pubitemid 38656388)
78. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Ho J. K., Bar-Or A., Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. Journal of Immunology 2007 178 10 6092 6099 2-s2.0-34248230257 (Pubitemid 46717389)
79. Bar-Or A., Fawaz L., Fan B., Darlington P. J., Rieger A., Ghorayeb C., Calabresi P. A., Waubant E., Hauser S. L., Zhang J., Smith C. H., Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Annals of Neurology 2010 67 4 452 461 2-s2.0-77951757865 10.1002/ana.21939
80. Hawker K., O'Connor P., Freedman M. S., Calabresi P. A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C. H., Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology 2009 66 4 460 471 2-s2.0-70449418132 10.1002/ana.21867
81. Hauser S. L., Waubant E., Arnold D. L., Vollmer T., Antel J., Fox R. J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C. H., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. The New England Journal of Medicine 2008 358 7 676 688 2-s2.0-39049142995 10.1056/NEJMoa0706383 (Pubitemid 351240747)
82. Monson N. L., Cravens P. D., Frohman E. M., Hawker K., Racke M. K., Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Archives of Neurology 2005 62 2 258 264 2-s2.0-13444274684 10.1001/archneur.62.2.258 (Pubitemid 40204747)
83. Kappos L., Li D., Calabresi P. A., O'Connor P., Bar-Or A., Barkhof F., Yin M., Leppert D., Glanzman R., Tinbergen J., Hauser S. L., Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. The Lancet 2011 378 9805 1779 1787 2-s2.0-81555202418 10.1016/S0140-6736(11)61649-8
84. Lulu S., Waubant E., Humoral-targeted immunotherapies in multiple sclerosis. Neurotherapeutics 2013 10 1 34 43
85. Hensley S. E., Zanker D., Dolan B. P., David A., Hickman H. D., Embry A. C., Skon C. N., Grebe K. M., Griffin T. A., Chen W., Bennink J. R., Yewdell J. W., Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. Journal of Immunology 2010 184 8 4115 4122 2-s2.0-77952770300 10.4049/jimmunol.0903003
86. Maldonado M., Kapphahn R. J., Terluk M. R., Heuss N. D., Yuan C., Gregerson D. S., Ferrington D. A., Immunoproteasome deficiency modifies the alternative pathway of NFkappaB signaling. PLoS ONE 2013 8 2 e56187
87. Lin M. W., Suan D., Lenton K., Henniker T., Burke T., Vucic S., Fulcher D. A., Differentiating patterns of oligoclonal banding in the cerebrospinal fluid improves diagnostic utility for multiple sclerosis. Pathology 2012 44 3 248 250
88. Stich O., Jarius S., Kleer B., Rasiah C., Voltz R., Rauer S., Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. Journal of Neuroimmunology 2007 183 1-2 220 224 2-s2.0-33846820308 10.1016/j.jneuroim.2006.11.008 (Pubitemid 46204909)
89. Storch M. K., Piddlesden S., Haltia M., Iivanainen M., Morgan P., Lassmann H., Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination. Annals of Neurology 1998 43 4 465 471 2-s2.0-0031748566 10.1002/ana.410430409 (Pubitemid 28231721)
90. Mayo I., Arribas J., Villoslada P., DoForno R. A., Rodríguez- Vilariño S., Montalban X., De Sagarra M. R., Castaño J. G., The proteasome is a major autoantigen in multiple sclerosis. Brain 2002 125 12 2658 2667 2-s2.0-0036895612 (Pubitemid 35423515)
91. Thuy-Tien H., Haugen M., Aarseth J., Storstein A., Vedeler C. A., Proteasome antibodies in patients with cancer or multiple sclerosis. Scandinavian Journal of Immunology 2008 67 4 400 403 2-s2.0-40849083783 10.1111/j.1365-3083.2008.02073.x (Pubitemid 351392922)
92. Beyer N. H., Milthers J., Lauridsen B. A.-M., Houen G., Frederiksen L. J., Autoantibodies to the proteasome in monosymptomatic optic neuritis may predict progression to multiple sclerosis. Scandinavian Journal of Clinical and Laboratory Investigation 2007 67 7 696 706 2-s2.0-35649006958 10.1080/00365510701342062 (Pubitemid 350034644)
93. Brychcy M., Kuckelkorn U., Hausdorf G., Egerer K., Kloetzel P.-M., Burmester G.-R., Feist E., Anti-20S proteasome autoantibodies inhibit proteasome stimulation by proteasome activator PA28. Arthritis and Rheumatism 2006 54 7 2175 2183 2-s2.0-33745890229 10.1002/art.21970 (Pubitemid 44051074)
94. Sixt S. U., Dahlmann B., Extracellular, circulating proteasomes and ubiquitin: incidence and relevance. Biochimica et Biophysica Acta 2008 1782 12 817 823 2-s2.0-56449112645 10.1016/j.bbadis.2008.06.005
95. Jakob C., Egerer K., Liebisch P., Türkmen S., Zavrski I., Kuckelkorn U., Heider U., Kaiser M., Fleissner C., Sterz J., Kleeberg L., Feist E., Burmester G.-R., Kloetzel P.-M., Sezer O., Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007 109 5 2100 2105 2-s2.0-33847380754 10.1182/blood-2006-04-016360 (Pubitemid 46348211)
96. Mueller O., Anlasik T., Wiedemann J., Thomassen J., Wohlschlaeger J., Hagel V., Keyvani K., Schwieger I., Dahlmann B., Sure U., Sixt S. U., Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity. Journal of Molecular Neuroscience 2012 46 3 509 515 2-s2.0-84859155913 10.1007/s12031-011-9631-2
97. Lai R. C., Tan S. S., Teh B. J., Sze S. K., Arslan F., de Kleijn D. P., Choo A., Lim S. K., Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. International Journal of Proteomics 2012 2012 14 971907 10.1155/2012/971907
98. Roth G. A., Moser B., Krenn C., Roth-Walter F., Hetz H., Richter S., Brunner M., Jensen-Jarolim E., Wolner E., Hoetzenecker K., Boltz-Nitulescu G., Ankersmit H. J., Heightened levels of circulating 20S proteasome in critically ill patients. European Journal of Clinical Investigation 2005 35 6 399 403 2-s2.0-20444477186 10.1111/j.1365-2362.2005.01508.x (Pubitemid 40826839)
99. Minagar A., Ma W., Zhang X., Wang X., Zhang K., Alexander J. S., Gonzalez-Toledo E., Albitar M., Plasma ubiquitin-proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b. Journal of Neurology Research 2012 34 6 611 618
100. Stadelmann C., Wegner C., Brück W., Inflammation, demyelination, and degeneration: recent insights from MS pathology. Biochimica et Biophysica Acta 2011 1812 2 275 282 2-s2.0-78650172976 10.1016/j.bbadis.2010.07.007
101. Gonsette R. E., Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. Journal of the Neurological Sciences 2008 274 1-2 48 53 2-s2.0-53049093018 10.1016/j.jns.2008.06.029
102. Lassmann H., van Horssen J., The molecular basis of neurodegeneration in multiple sclerosis. FEBS Letters 2011 585 23 3715 3723 2-s2.0-81555223903 10.1016/j.febslet.2011.08.004
103. Haider L., Fischer M. T., Frischer J. M., Bauer J., Höftberger R., Botond G., Esterbauer H., Binder C. J., Witztum J. L., Lassmann H., Oxidative damage in multiple sclerosis lesions. Brain 2011 134 7 1914 1924 2-s2.0-79959723400 10.1093/brain/awr128
104. Smerjac S. M., Bizzozero O. A., Cytoskeletal protein carbonylation and degradation in experimental autoimmune encephalomyelitis. Journal of Neurochemistry 2008 105 3 763 772 2-s2.0-42449141602 10.1111/j.1471-4159.2007. 05178.x (Pubitemid 351562723)
105. Zheng J., Bizzozero O. A., Accumulation of protein carbonyls within cerebellar astrocytes in murine experimental autoimmune encephalomyelitis. Journal of Neuroscience Research 2010 88 15 3376 3385 2-s2.0-78649392988 10.1002/jnr.22488
106. Papa L., Rockwell P., Persistent mitochondrial dysfunction and oxidative stress hinder neuronal cell recovery from reversible proteasome inhibition. Apoptosis 2008 13 4 588 599 2-s2.0-41149164588 10.1007/s10495-008-0182-0
107. Sullivan P. G., Dragicevic N. B., Deng J.-H., Bai Y., Dimayuga E., Ding Q., Chen Q., Bruce-Keller A. J., Keller J. N., Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. Journal of Biological Chemistry 2004 279 20 20699 20707 2-s2.0-2442645048 10.1074/jbc.M313579200 (Pubitemid 38656466)
108. Aiken C. T., Kaake R. M., Wang X., Huang L., Oxidative stress-mediated regulation of proteasome complexes. Molecular and Cellular Proteomics 2011 10 5 R110.006924 2-s2.0-79955757695 10.1074/mcp.R110.006924
109. Grimm S., Höhn A., Grune T., Oxidative protein damage and the proteasome. Amino acids 2012 42 1 23 38 2-s2.0-79959534486 10.1007/s00726-010- 0646-8
110. Jung T., Grune T., The proteasome and its role in the degradation of oxidized proteins. IUBMB Life 2008 60 11 743 752 2-s2.0-58149350129 10.1002/iub.114
111. Grune T., Merker K., Sandig G., Davies K. J. A., Selective degradation of oxidatively modified protein substrates by the proteasome. Biochemical and Biophysical Research Communications 2003 305 3 709 718 2-s2.0-0038239701 10.1016/S0006-291X(03)00809-X (Pubitemid 36579287)
112. Farout L., Friguet B., Proteasome function in aging and oxidative stress: implications in protein maintenance failure. Antioxidants and Redox Signaling 2006 8 1-2 205 216 2-s2.0-33644662970 10.1089/ars.2006.8.205 (Pubitemid 43324547)
113. Reinheckel T., Sitte N., Ullrich O., Kuckelkorn U., Davies K. J. A., Grune T., Comparative resistance of the 20 S and 26 S proteasome to oxidative stress. Biochemical Journal 1998 335 3 637 642 2-s2.0-0032212875
114. Kästle M., Grune T., Proteins bearing oxidation-induced carbonyl groups are not preferentially ubiquitinated. Biochimie 2011 93 6 1076 1079 2-s2.0-79955063530 10.1016/j.biochi.2011.03.004
115. Kotamraju S., Matalon S., Matsunaga T., Shang T., Hickman-Davis J. M., Kalyanaraman B., Upregulation of immunoproteasomes by nitric oxide: potential antioxidative mechanism in endothelial cells. Free Radical Biology and Medicine 2006 40 6 1034 1044 2-s2.0-33644852960 10.1016/j.freeradbiomed.2005.10.052 (Pubitemid 43376013)
116. Pickering A.M.,Koop A.L.,Teoh C.Y.,Ermak G.,Grune T.,Davies K.J.A.,The immunoproteasome,the 20S proteasome and the PA28 β proteasome regulator are oxidative-stress-adaptive proteolytic complexes. Biochemical Journal 2010 432 3 585 594 2-s2.0-78649848069 10.1042/BJ20100878
117. Pickering A. M., Davies K. J., Differential roles of proteasome and immunoproteasome regulators Pa28alphabeta, Pa28gamma and Pa200 in the degradation of oxidized proteins. Archives of Biochemistry and Biophysics 2012 523 2 181 190
118. Ding Q., Martin S., Dimayuga E., Bruce-Keller A. J., Keller J. N., LMP2 knock-out mice have reduced proteasome activities and increased levels of oxidatively damaged proteins. Antioxidants and Redox Signaling 2006 8 1-2 130 135 2-s2.0-33644656207 10.1089/ars.2006.8.130 (Pubitemid 43324539)
119. Bates D., Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011 76 1 supplement 1 S14 S25 2-s2.0-78751613188 10.1212/WNL.0b013e3182050388
120. Lucchinetti C. F., Parisi J., Bruck W., The pathology of multiple sclerosis. Neurologic Clinics 2005 23 1 77 105 2-s2.0-12344335574 10.1016/j.ncl.2004.09.002 (Pubitemid 40126916)
121. Frisullo G., Plantone D., Marti A., Iorio R., Damato V., Nociti V., Patanella A. K., Bianco A., Batocchi A. P., Type 1 immune response in progressive multiple sclerosis. Journal of Neuroimmunology 2012 249 1-2 112 116
122. Bellavista E., Andreoli F., Parenti M., Martucci M., Santoro A., Salvioli S., Capri M., Baruzzi A., Del Rio A., Franceschi C., Mishto M., Immunoproteasome in cancer and neuropathologies: a new therapeutic target? Current Pharmaceutical Design 2013 19 4 702 718
123. Perchellet A., Stromnes I., Pang J. M., Goverman J., CD8+ T cells maintain tolerance to myelin basis protein by 'epitope theft'. Nature Immunology 2004 5 6 606 614 2-s2.0-2942666042 10.1038/ni1073 (Pubitemid 38811885)
124. Friese M. A., Jakobsen K. B., Friis L., Etzensperger R., Craner M. J., McMahon R. M., Jensen L. T., Huygelen V., Jones E. Y., Bell J. I., Fugger L., Opposing effects of HLA class I molecules in tuning autoreactive CD8 + T cells in multiple sclerosis. Nature Medicine 2008 14 11 1227 1235 2-s2.0-55549104692 10.1038/nm.1881
125. Human Microbiome Project Consortium, Structure, function and diversity of the healthy human microbiome. Nature 2012 486 7402 207 214
126. Candela M., Biagi E., Maccaferri S., Turroni S., Brigidi P., Intestinal microbiota is a plastic factor responding to environmental changes. Trends in Microbiology 2012 20 8 385 391
127. Perchellet A., Brabb T., Goverman J. M., Crosspresentation by nonhematopoietic and direct presentation by hematopoietic cells induce central tolerance to myelin basic protein. Proceedings of the National Academy of Sciences of the United States of America 2008 105 37 14040 14045 2-s2.0-52949084680 10.1073/pnas.0804970105